Anesthesia, ICU & Pain ManagementMedically reviewed

    Intravenous Anesthetics: Pharmacology and Clinical Selection

    A practical review of intravenous anesthetic pharmacokinetics, mechanisms, clinical profiles, and safety considerations.

    1 views0 likes5 sectionsReviewed 2 Aug 2026 · Mohamed Nasser
    01Pharmacokinetic framework

    Intravenous administration provides complete systemic bioavailability. The onset of hypnosis is dominated by circulation time, lipid solubility, ionization, protein binding, and delivery to the vessel-rich brain.

    After an induction bolus, redistribution from brain to muscle and other tissues often lowers the effect-site concentration before substantial elimination has occurred. Repeated boluses or prolonged infusions can fill peripheral compartments and delay recovery.

    • Albumin commonly binds acidic drugs, while alpha-1 acid glycoprotein binds many basic drugs.
    • Only unbound drug readily crosses membranes and reaches receptors.
    • Hepatic metabolism and renal or biliary elimination become increasingly important as exposure continues.
    • Context-sensitive recovery depends on both clearance and accumulation in tissue compartments.
    02Thiopental and propofol

    Thiopental is an ultrashort-acting barbiturate that positively modulates GABA-A receptors. Rapid brain uptake produces hypnosis, while redistribution explains early awakening after a single bolus. It can reduce cerebral metabolic demand and intracranial pressure, but it can cause hypotension, respiratory depression, tissue injury after extravasation, and acute porphyria in susceptible patients.

    Propofol is a lipid-emulsion intravenous anesthetic that enhances GABA-A signaling. It supports induction, maintenance of total intravenous anesthesia, and procedural or ICU sedation in appropriate settings. Rapid redistribution and high clearance permit prompt recovery after many short exposures.

    • Propofol commonly produces dose-dependent hypotension, bradycardia, and respiratory depression.
    • Pain on injection is common, and strict aseptic handling is essential because formulations support microbial growth.
    • Prolonged high-dose infusions can be associated with propofol infusion syndrome, including metabolic acidosis, rhabdomyolysis, cardiovascular collapse, and organ dysfunction.
    03Ketamine, etomidate, and dexmedetomidine

    Ketamine is primarily an NMDA-receptor antagonist that produces dissociative anesthesia, analgesia, and amnesia. Sympathetic stimulation often increases heart rate and blood pressure, although cardiovascular depression may emerge in catecholamine-depleted patients. Bronchodilation can be useful, but respiratory depression, laryngospasm, and loss of protective reflexes remain possible.

    Etomidate enhances GABA-A signaling and generally causes less cardiovascular depression than many induction alternatives. Its limitations include pain on injection, myoclonus, postoperative nausea and vomiting, and inhibition of adrenal steroid synthesis; continuous maintenance infusions are therefore generally avoided.

    Dexmedetomidine is a selective alpha-2 agonist that provides sedation, anxiolysis, sympatholysis, and some analgesic sparing with relatively limited respiratory depression. Bradycardia and hypotension are important adverse effects, and rapid loading can cause transient hypertension.

    04Choosing an intravenous agent

    Agent selection is contextual rather than absolute. Hemodynamic reserve, airway reactivity, neurologic disease, adrenal risk, recovery goals, concurrent medications, and the required depth and duration of anesthesia all matter.

    • Propofol favors smooth, rapidly titratable anesthesia but can markedly reduce blood pressure and ventilation.
    • Ketamine provides analgesia and often supports sympathetic tone but can cause emergence phenomena and increased secretions.
    • Etomidate offers relative hemodynamic stability but suppresses adrenal steroid synthesis.
    • Dexmedetomidine is useful for cooperative sedation but may cause clinically important bradycardia.
    • Thiopental has rapid onset but accumulates with repeated dosing and is contraindicated in acute porphyrias.
    05Source and verification note

    Primary teaching source: Akram Amer, Pharmacology of Anesthesia Drugs, pages 1-10.

    Safety-sensitive claims were cross-checked against current human prescribing information for propofol and ketamine and against contemporary anesthesia references.

    This material is educational and remains a draft until reviewed by a qualified clinician. Local protocols and current product information take precedence for patient care.